发明授权
EP3116860B1 SULFONAMIDES DERIVED FROM TRICYCLYL-2-AMINOCYCLOALKANOLS AS ANTICANCER AGENTS
有权
衍生自三环-2-氨基卡诺醇作为抗癌剂的磺酰胺
- 专利标题： SULFONAMIDES DERIVED FROM TRICYCLYL-2-AMINOCYCLOALKANOLS AS ANTICANCER AGENTS
- 专利标题（中）： 衍生自三环-2-氨基卡诺醇作为抗癌剂的磺酰胺
-
申请号： EP15712746.5申请日： 2015-03-10
-
公开(公告)号： EP3116860B1公开(公告)日： 2018-02-07
- 发明人: OHLMEYER, Michael , KASTRINSKY, David
- 申请人： Icahn School of Medicine at Mount Sinai
- 申请人地址： One Gustave L. Levy Place New York, NY 10029 US
- 专利权人： Icahn School of Medicine at Mount Sinai
- 当前专利权人： Icahn School of Medicine at Mount Sinai
- 当前专利权人地址： One Gustave L. Levy Place New York, NY 10029 US
- 代理机构： Hutchins, Michael Richard
- 优先权： US201461951237P 20140311
- 国际公布： WO2015138500 20150917
- 主分类号： C07D243/38
- IPC分类号： C07D243/38 ; C07C311/29 ; C07D471/04 ; C07D265/38 ; C07D267/18 ; C07D495/04 ; C07D209/86 ; A61K31/538 ; A61K31/553 ; A61K31/404 ; A61K31/551 ; A61K31/519 ; A61K31/407 ; A61K31/437 ; A61P35/00 ; A61P3/10 ; A61P37/00
摘要：
The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.
公开/授权文献
信息查询
